Which is better, AUPH or HRMY?

On the Buffett-Fit framework, Harmony Biosciences Holdings, Inc. (HRMY) currently grades higher than AUPH — 67/100 (B grade) vs 56/100 (C). That said, "better" depends on which framework you trust — AUPH wins on Peter Lynch and Joel Greenblatt; HRMY wins on Warren Buffett, Benjamin Graham, Philip Fisher, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy AUPH or HRMY?

This page is an educational comparison, not investment advice. Both AUPH and HRMY are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is AUPH better than HRMY for value investing?

On the Buffett-style value-investing framework, HRMY currently grades higher — 67/100 vs 56/100, a 11-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between AUPH and HRMY on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). AUPH currently scores 56/100 (C grade); HRMY scores 67/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, AUPH or HRMY?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. AUPH and HRMY are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, AUPH or HRMY?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are AUPH and HRMY both Healthcare stocks?

Yes — both Aurinia Pharmaceuticals Inc. (AUPH) and Harmony Biosciences Holdings, Inc. (HRMY) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this AUPH vs HRMY comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Aurinia Pharmaceuticals

Harmony Biosciences Holdings

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

AUPH

Market cap

$1.96B

Sector

Healthcare

HRMY

Harmony Biosciences Holdings

Market cap

$1.75B

Sector

Healthcare

Overall winner

Harmony Biosciences Holdings HRMY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	AUPH	HRMY	Winner
Warren Buffett	56C	67B	HRMY
Benjamin Graham	54D	60C	HRMY
Philip Fisher	59C	75B	HRMY
Peter Lynch	81A	62C	AUPH
Joel Greenblatt	63C	28F	AUPH
Charlie Munger	49D	62C	HRMY
Terry Smith	48D	67B	HRMY

Side-by-side metrics

Metric	AUPH	HRMY
Market cap	$1.96B	$1.75B
P/E (TTM)	6.9x	11.8x
EV/EBIT	19.4x	6.4x
ROIC (TTM)	18.99%	12.5%
Gross margin	89.74%	76.55%
Net margin	99.97%	16.2%
Revenue CAGR 5y	57.84%	29.85%
EPS CAGR 5y	-	46.45%
Debt / Equity	0.1x	0.2x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

AUPH leads on

Net margin99.97%vs 16.2%+84%
Revenue CAGR 5y57.84%vs 29.85%+48%
Debt / Equity0.1xvs 0.2x+47%
P/E (TTM)6.9xvs 11.8x+42%

HRMY leads on

EV/EBIT6.4xvs 19.4x+67%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Aurinia Pharmaceuticals

Harmony Biosciences Holdings

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like AUPH

More like HRMY

Related on invest-like

Key terms in this analysis